Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 97
Selected: 0
NCT IDTitle
NCT02163720Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
NCT04784559Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT01846611A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01273493A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
NCT00780975A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
NCT02533674Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
NCT04305548Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
NCT05705167Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
NCT03127215Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
NCT02398058Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
NCT01951157A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00113607An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT05285033RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
NCT07644039Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
NCT00580112An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
NCT00884845Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
NCT05835609PM534 Administered Intravenously to Patients With Advanced Solid Tumors
NCT02566993Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
NCT07839819Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT02611024Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT06088290Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06050434Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
NCT02100657Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
NCT02454972Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
NCT00359294A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
NCT01149681Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT04383119Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT05121740Extension Study in a Cohort of Adult Patients With COVID-19 Infection
NCT01405391Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
NCT05076396PM14 Administered Intravenously to Patients With Advanced Solid Tumors
NCT00884286Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
NCT02194231ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
NCT00877474Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
NCT00102609A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
NCT02451007Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
NCT02204111Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
NCT01970540Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
NCT01525589A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
NCT00404521A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
NCT00147212ET 743 (Yondelis) in Men With Advanced Prostate Cancer
NCT05101265Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
NCT03085225Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
NCT05063318Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
NCT02684318Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
NCT00050427A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
NCT02421588Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
NCT04358237Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT01343277A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
NCT01876043Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial